{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:30:01Z","timestamp":1787923801142,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008358","name":"Brain Foundation","doi-asserted-by":"publisher","award":["HA2015.01.05"],"award-info":[{"award-number":["HA2015.01.05"]}],"id":[{"id":"10.13039\/501100008358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003000","name":"Multiple Sclerosis Research Foundation","doi-asserted-by":"publisher","award":["23-1207"],"award-info":[{"award-number":["23-1207"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003000","name":"Multiple Sclerosis Research Foundation","doi-asserted-by":"publisher","award":["18-1030"],"award-info":[{"award-number":["18-1030"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009248","name":"Innovation Fund for Health Insurers","doi-asserted-by":"publisher","award":["B 18-313\/ File 3.798"],"award-info":[{"award-number":["B 18-313\/ File 3.798"]}],"id":[{"id":"10.13039\/501100009248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107409","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:28:33Z","timestamp":1785086913000},"page":"107409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4864-1429","authenticated-orcid":false,"given":"Liza M.Y.","family":"Gelissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia A.","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa A.","family":"Toorop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo P.J.","family":"Arnoldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.C.","family":"Beenakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.J.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Eurelings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"van Genugten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno N.","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin L.J.","family":"Hoogervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke F.","family":"Kalkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Kloosterziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolijn J.","family":"Kragt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop P.","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar","family":"van Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk C.","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan M.","family":"Roosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs H.A.","family":"Wokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.P.E.","family":"Zeinstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M.J.","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos W.R.","family":"Twisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9 L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107409_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM)., using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcom."},{"key":"10.1016\/j.msard.2026.107409_bib0002","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/13524585251346374","article-title":"Should natalizumab be used despite JC virus positivity? Yes","volume":"31","author":"Carroll","year":"2025","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107409_bib0003","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1177\/13524585251346382","article-title":"Should natalizumab be used despite JC virus positivity? No","volume":"31","author":"Dalla Costa","year":"2025","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107409_bib0004","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA).: a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107409_bib0005","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/PPA.S134865","article-title":"Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis","volume":"11","author":"Foley","year":"2017","journal-title":"Patient. Prefer. Adherenc."},{"key":"10.1016\/j.msard.2026.107409_bib0006","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2024-335761","article-title":"Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis","volume":"96","author":"Gelissen","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107409_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7224\/1537-2073.2013-021","article-title":"Treatment satisfaction in multiple sclerosis","volume":"16","author":"Glanz","year":"2014","journal-title":"Int. J. MS. Care"},{"key":"10.1016\/j.msard.2026.107409_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00415-022-11408-0","article-title":"Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic","volume":"270","author":"Magro","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107409_bib0009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/nmt-2021-0038","article-title":"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis","volume":"12","author":"Moccia","year":"2022","journal-title":"Neurodegener. Dis. Manage"},{"key":"10.1016\/j.msard.2026.107409_bib0010","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00415-017-8643-4","article-title":"Natalizumab therapy is associated with changes in serum JC virus antibody indices over time","volume":"264","author":"Peters","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107409_bib0011","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107409_bib0012","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107409_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104561","article-title":"Exploratory clinical efficacy and patient-reported outcomes from NOVA: a randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis","volume":"72","author":"Ryerson","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107409_bib0014","article-title":"Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107409_bib0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1177\/13524585241293940","article-title":"Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients","volume":"30","author":"Toorop","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107409_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123102","article-title":"Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial","volume":"462","author":"Toorop","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107409_bib0017","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600444X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600444X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:51:10Z","timestamp":1787921470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600444X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"alternative-id":["S221103482600444X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107409","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107409"}}